This website uses technical, analytics and third party cookies.
By continuing to browse, you accept our cookies.

Privacy policy

  • Go to content
  • Browse the site
Menu
Italian Medicines Agency

Italian Medicines Agency

Follow us on

  • Facebook
  • Twitter
  • Youtube

Language Selector

  • ITA
  • ENG
 
 
 

label.navivation.menu

  • The Agency
    • The Agency
    • Mission and values
    • Organisation
    • Technical and advisory committees
    • Support and Coordination Secretariats and Advisory Committees
    • International Collaborations
    • Legislation
    • Forms
    • Competition notices
    • Resolutions
    • Tenders and contracts
    • Quality assurance
    • Guarantee Committee
    • Open AIFA
    • Contacts
    • Certified email
  • COVID-19 Emergency
    • COVID-19 Emergency
    • COVID-19 Vaccines
    • Medicines usable for treatment of COVID-19 disease
    • Monitoring of medicinal products used during the COVID-19 epidemic
    • Recommendations on use of medicines in the population exposed to the virus
    • Clinical Trials - COVID-19
    • Compassionate Use Programs - COVID-19
    • COVID-19 Emergency Donations
    • Authorised import procedures - COVID-19 Emergency 
  • Access to medicinal products
    • Access to medicinal products
    • Early access and off-label use
    • Authorisation of medicinal products
    • Medicine shortages
    • Antibiotic medicinal products
    • Biological medicinal products
    • Vaccines
    • Blood derivatives
    • Generic medicinal products
    • Biosimilar medicinal products
    • Orphan medicinal products
    • Advanced therapies
    • Homeopathic medicinal products
    • Allergens
  • Safety of medicinal products
    • Safety of medicinal products
    • Pharmacovigilance 
    • National Pharmacovigilance Network
    • The RAM System
    • Persons in charge of Pharmacovigilance
    • European Eudravigilance System
    • Adverse Reactions to medicinal products
    • Regional pharmacovigilance funds
    • Pharmacovigilance signals
    • PSURs (Periodic safety update reports)
    • Risk management measures
    • Medicinal products subject to additional monitoring
  • Quality and Inspections
    • Quality and Inspections
    • Quality defects
    • Inspections and authorisations
    • Qualified person
    • Fight of pharmaceutical crime
  • Research and Clinical trials
    • Research and Clinical trials
    • Clinical trials concerning medicinal products
    • National Observatory on Clinical Trials
    • Ethical Committees Coordination Centre
    • Independent clinical research
  • Pricing and reimbursement
    • Pricing and reimbursement
    • Negotiation and reimbursement
    • Economic evaluations
    • Monitoring Registers
    • AIFA Notes
    • Lists of Class A and Class H medicinal products
    • Innovative medicinal products
    • Transparency Lists
  • Consumption and pharmaceutical expenditure
    • Consumption and pharmaceutical expenditure
    • The Medicines Utilization Monitoring Centre (OsMed) 
    • Governance of pharmaceutical expenditure
    • Monitoring pharmaceutical expenditure
  • Innovation and planning
    • Innovation and planning
    • Innovation and scientific advice
    • Horizon scanning
  • Information and communication
    • Information and communication
    • FarmaciLine
    • Medical and scientific information
    • Questions and answers
    • Publications
    • AIFA editorials
    • Public consultations
    • Documents shared with scientific communities 
    • World news
    • Communication campaigns
    • Press corner
    • Archive
  • AIFA data
    • AIFA data
    • OsMed Data
    • Open Data
  • Administrative services
    • Administrative services
    • Requests for authorisation of conferences and meetings
    • Service of administrative documents
    • Payment of fees and annual duties
    • MA Electronic invoicing
  • Open governance
    • Open governance
    • Disposizioni Generali
    • Organizzazione
    • Consulenti e collaboratori
    • Personale
    • Bandi di Concorso
    • Performance
    • Enti controllati
    • Attività e procedimenti
    • Provvedimenti
    • Bandi di gara e contratti
    • Sovvenzioni, contributi, sussidi, vantaggi economici
    • Bilanci
    • Beni immobili e gestione patrimonio
    • Controlli e rilievi sull'Amministrazione
    • Servizi Erogati
    • Pagamenti dell'Amministrazione
    • Opere pubbliche
    • Pianificazione e governo del territorio
    • Informazioni ambientali
    • Interventi straordinari di emergenza
    • Altri Contenuti
Italian Medicines Agency Agenzia Italiana del Farmaco

Sovvenzioni, contributi, sussidi, vantaggi economici

Breadcrumb

  • Home
  • Open governance
  • Sovvenzioni, contributi, sussidi, vantaggi economici

Sovvenzioni, contributi, sussidi, vantaggi economici

La sezione è disponibile come indicato nel DLgs 33/2013 novellato dal D. Lgs 97/2016 e come indicato dalla Delibera ANAC 1310/2016

Site Map

  • Criteri e modalità
  • Atti di concessione

Site Map

Open governance

  • Disposizioni Generali
  • Organizzazione
  • Consulenti e collaboratori
  • Personale
  • Bandi di Concorso
  • Performance
  • Enti controllati
  • Attività e procedimenti
  • Provvedimenti
  • Bandi di gara e contratti
  • Sovvenzioni, contributi, sussidi, vantaggi economici
    • Criteri e modalità
    • Atti di concessione
  • Bilanci
  • Beni immobili e gestione patrimonio
  • Controlli e rilievi sull'Amministrazione
  • Servizi Erogati
  • Pagamenti dell'Amministrazione
  • Opere pubbliche
  • Pianificazione e governo del territorio
  • Informazioni ambientali
  • Interventi straordinari di emergenza
  • Altri Contenuti

Share

The Agency

  • Home Page >
  • Farmaciline >
  • User participation and satisfaction >
  • Citizens' access >
  • Open governance >

Contacts

  • Via del Tritone, 181
    00187 Rome
  • Contacts >
  • Certified e-mail (PEC) contacts >
  • VAT number: 08703841000
    Tax code: 97345810580
    IPA code: UFE1TR

Follow us on

  • Facebook
  • Twitter
  • Youtube
  • Legal notice
  • Sitemap
  • Web accessibility
  • Website statistics
  • Privacy
  • Online services
  • Intranet
go to beginning of content